NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nagi Bioscience SA

Nagi Bioscience SA

Private
Saint-SulpiceHealthcare & Life Scienceshttps://nagibio.ch/

Last Round

Series A

Sep 28, 2023

Total Funding Raised

$18.4M

Company Overview

Nagi Bioscience SA is a biotechnology company that develops and provides organism-on-chip technology for automated biological testing as an alternative to animal testing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

high-throughput screeningmicrofluidicsC. elegansdrug discoverytoxicity testinganimal testing alternativeslab automationhigh-content imagingphenotypic screeningin vitro testingcontract research organizationCROorgan-on-a-chipnew approach methodologiesNAMsrazor-and-blade model

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nagi Bioscience SA Comparables

Compare Nagi Bioscience SA with similar companies based on industry and business-model similarity.

Nagi Bioscience SA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NemaLife
82%
ElegsLab
80%
Magnitude Biosciences
78%

Nagi Bioscience SA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 28, 2023
GrantMar 21, 2022
SeedDec 20, 2019
AcceleratorJan 31, 2019
GrantJul 4, 2018

Key People

Founding team and executive leadership

Matteo Cornaglia

CEO & founder

Founding Team

Nagi Bioscience SA Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2025

    Rhino Bio Inc. will distribute analytical systems in South Korea.

Nagi Bioscience SA Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nagi Bioscience SA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nagi Bioscience SA's valuation, stock price, and market status.

Firmographic Details

HeadquartersSaint-Sulpice
Employee Range54
Year Founded2019
Last FundingSep 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.